rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PFE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases
      11h agoBenzingaPFE
      Pfizer: The Patent Cliff Fears Are Overblown

      Analyst rates Pfizer Inc. a Buy as oncology, Eliquis and tafamidis may offset its three-year patent cycle; 2026 EPS guidance rises to $2.95-$3.05.

      12h agoSeeking AlphaPFE
      Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal
      14h agoReutersPFE
      Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

      Pfizer (PFE) pays China-based Starna Therapeutics $330M upfront to receive ex-China rights to CAR-T drugs in a deal worth up to $2.6B. Read more here.

      15h agoSeeking AlphaPFE
      Pfizer licenses in vivo CAR-T programs from Starna for $330M
      15h agoInvesting.comPFE
      Pfizer: Strong Growth Momentum And Attractive Valuation Support A Strong Buy

      At 9.6 times guidance-midpoint earnings with a 5.95% dividend yield, Pfizer stock looks inexpensive.

      21h agoSeeking AlphaPFE
      Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
      Nov 17Yahoo FinancePFE
      Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitions
      Nov 17Yahoo FinancePFE
      Pfizer at jefferies global healthcare conference: pipeline, ai and loe
      Nov 17Investing.comJEFPFE
      Barclays Keeps Their Sell Rating on Pfizer (PFE)

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Nov 17The Globe and MailPFE
      Pfizer (PFE) Re Enters Obesity Drugs With Metsera Acquisition
      Nov 17Yahoo FinancePFE
      2 Stocks With Dividend Yields of 4% or More to Buy in November

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Nov 16The Globe and MailPFE
      The Zacks Analyst Blog Highlights Visa, ExxonMobil Holdings and Pfizer
      Nov 16Yahoo FinancePFE
      One Unsettled Question Sits Under Pfizer Stock
      Nov 16Yahoo FinancePFE
      Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes
      Nov 14ReutersPFE
      Pfizer (PFE) Secures $1.5 Billion For Berobenatide Development
      Nov 14Yahoo FinanceBXPFE
      Top Stock Reports for Visa, ExxonMobil & Pfizer
      Nov 13Yahoo FinancePFEV
      Blackstone is becoming a biotech bank
      Nov 13AxiosBXPFE
      Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market
      Nov 13BenzingaPFE
      A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer
      Nov 13Yahoo FinancePFE
      Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?
      Nov 13Yahoo FinancePFE
      Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

      Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity.

      Nov 12Seeking AlphaPFE
      Pfizer offshoot Zoetis lines up 'potential blockbuster' pet meds for Japan

      More players enter growing market as domestic spending per animal rises

      Nov 12NikkeiPFEZTS
      EXCLUSIVE: Pfizer to stop selling Premarin hormone therapy in Canada
      Nov 12ReutersPFE
      Belgian court sets aside Pfizer-linked seizure of Polish air traffic funds
      Nov 12ReutersPFE
      Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund
      Nov 12Yahoo FinanceBXPFE
      Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy
      Nov 12Yahoo FinanceBXPFE
      Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

      Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based payments.

      Nov 12Barron'sPFE
      Bernstein reiterates Pfizer stock rating after earnings beat
      Nov 12Investing.comPFE
      Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales
      Nov 12BenzingaBXPFE
      Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program
      Nov 12Yahoo FinanceBXPFE
      Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
      Nov 11ReutersBXPFE
      Blackstone Puts Up $1.5 Billion for Pfizer Obesity Drug Studies
      Nov 11BloombergBXPFE
      Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

      The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.

      Nov 11WSJBXPFE
      Pfizer secures up to $1.5 billion from Blackstone for obesity drug development By Reuters
      Nov 11Investing.comBXPFE
      Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
      Nov 11Yahoo FinanceBXPFE
      Pfizer (PFE) Posts Phase 3 ELREXFIO Win And Expands AI Research Push
      Nov 10Yahoo FinancePFE
      Pfizer’s comeback gets a new finance chief
      Nov 10Yahoo FinancePFE
      Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock
      Nov 10Yahoo FinancePFE
      Medicus Pharma Ltd (MDCX) Q3 2026 Earnings Call Highlights: Pfizer ADC License, SkinJet SPAC ...

      Medicus Pharma Ltd (MDCX) outlined its CD228V license from Pfizer, a proposed $135 million SkinJet SPAC combination and a $35.9 million nine-month net loss amid tight liquidity.

      Nov 10Yahoo FinancePFE
      Pfizer (PFE) Stock Looks Overvalued On Its 29% One Year Gain
      Nov 9Yahoo FinancePFE
      Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
      Nov 9Yahoo FinancePFE
      Medicus Pharma sharpens focus on Pfizer-licensed cancer drug CD228V, trims costs in Q3
      Nov 9Yahoo FinancePFE
      Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
      Nov 9Yahoo FinancePFE
      Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
      Nov 7Yahoo FinanceLLYNVOPFE
      Pfizer vs. AbbVie: Higher Yield and Cheaper Valuation Give One the Clear Edge
      Nov 7BarchartABBVPFE
      Pfizer (PFE) Maps Out $650 Million Connecticut Center For Global Clinical Trials
      Nov 6Yahoo FinancePFE
      Better Dividend Stock: Verizon vs. Pfizer
      Nov 6Yahoo FinancePFEVZ
      Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
      Nov 6Yahoo FinanceBNTXMRNAPFE
      Freedom Broker raises Pfizer stock price target on strong Q3 results
      Nov 6Investing.comPFE

      This is the newest page. Registered accounts read further back.